EtoposideAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsTopoisomerase II InhibitorsIfosfamideCisplatinCarcinoma, Small CellDNA Topoisomerases, Type IIPodophyllotoxinVincristineDoxorubicinCyclophosphamideCarboplatinAmsacrineDrug Administration ScheduleBleomycinLung NeoplasmsCombined Modality TherapyCytarabineGerminomaAntineoplastic AgentsTeniposideNucleic Acid Synthesis InhibitorsTopoisomerase InhibitorsLeukopeniaTransplantation, AutologousTesticular NeoplasmsDrug Resistance, NeoplasmMitoxantroneRemission InductionApoptosisNeoplasms, Germ Cell and EmbryonalTreatment OutcomeAdministration, OralDNA DamageHodgkin DiseaseInfusions, IntravenousCamptothecinCarmustineHematologic DiseasesDrug EvaluationSalvage TherapyLymphoma, Non-HodgkinTopotecanTopoisomerase I InhibitorsTumor Cells, CulturedDisease-Free SurvivalSurvival AnalysisRazoxaneNeutropeniaPrednisoneSurvival RateDrug ResistanceThrombocytopeniaDose-Response Relationship, DrugProcarbazineDrug Resistance, MultipleP-GlycoproteinOrganophosphorus CompoundsMelphalanPaclitaxelVinblastineCell SurvivalGranulocyte Colony-Stimulating FactorRetroperitoneal NeoplasmsAlopeciaDaunorubicinBone Marrow DiseasesHematopoietic Stem Cell TransplantationMethotrexateHL-60 CellsLevoleucovorinCell Line, TumorDrug SynergismSmall Cell Lung CarcinomaMesnaCaspasesDrug Screening Assays, AntitumorDNA Topoisomerases, Type I